about
Adaptive designs based on the truncated product methodDetecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.Statistical analysis of monotone or non-monotone dose-response data from in vitro toxicological assays.Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.Designing dose finding studies with an active control for exponential familiesExperimental designs for small randomised clinical trials: an algorithm for choice.Dose finding - a challenge in statistics.Adaptive designs for confirmatory clinical trials.Advanced multiplicity adjustment methods in clinical trials.Multiplicity and replicability: two sides of the same coin.Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.Model selection versus model averaging in dose finding studies.Estimands: discussion points from the PSI estimands and sensitivity expert group.A simple and flexible graphical approach for adaptive group-sequential clinical trials.Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials.Seventh international French Society of Statistics meeting on statistical methods in biopharmacy: emerging topics for statistical methodology in clinical drug development.Dose response signal detection under model uncertainty.Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.Authors' response to comments.Practical considerations for optimal designs in clinical dose finding studies.Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.Author's reply: To PMID 21837623.Multiple hypotheses testing based on ordered p values--a historical survey with applications to medical research.A graphical approach to sequentially rejective multiple test procedures.Panel forum on multiple comparison procedures: a commentary from a complex trial design and analysis plan.Model-based dose finding under model uncertainty using general parametric models.Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.Identifying effective and/or safe doses by stepwise confidence intervals for ratios.Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.Joint EMA, ISBS, and DR-IBS International Symposium on Biopharmaceutical Statistics: bridging drug development from research to marketing.Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests.Robustness considerations in selecting efficient two-color microarray designs.Power and sample size when multiple endpoints are considered.On the efficiency of two-stage response-adaptive designs.Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.Estimands in clinical trials - broadening the perspective.Sample size and proportion of Japanese patients in multi-regional trials.Assessing the similarity of dose response and target doses in 2 non-overlapping subgroups.Adaptive designs: The Swiss Army knife among clinical trial designs?
P50
Q24814317-8200F593-9999-478E-935B-8FAF4AC1202AQ30742989-F18C00A4-C92B-41BA-9F5C-785220EC3CF0Q30978354-A3433D9B-47A0-4DE7-A257-E017AF71E7E8Q36593604-25E657E1-3591-47B9-B3D0-A0C0E769EBD1Q36683934-97B82DB5-EDC0-4417-B707-CB53897BD355Q36793954-E3518FF9-09F5-466F-87F0-F831197AC68DQ37229350-D279B059-D82D-4FE6-B185-79722023EF4FQ37389417-BA65FC31-B825-479E-8334-9BE503560B8AQ38150794-16AE75C4-F1C8-4792-AE73-0D62B5D718ECQ38259464-CC8B640D-AE62-4459-8533-E4A24DB36555Q38380750-4803F8A9-F031-4114-92F5-8F1ECDD7A8D5Q38844527-5833BC97-6937-407E-9CA6-004CE92973FEQ39353907-746E4262-09C7-4CC2-B2C5-5DE31A8EAA17Q40009132-14D57A7A-F836-480B-BB82-0B049843CDD4Q40566508-F1C7BF5D-7A75-4FCA-BA76-1187AD8F7C08Q40581652-46A25898-5BCF-4EF3-8A62-D0490CDBE493Q40675281-A14F07C2-7293-486B-8071-255C860D3BCEQ40796122-DBC6F119-8146-440E-811D-3FA3F3AA75FBQ40983087-CC926311-0FF5-4465-86D3-34284B5C9643Q41820376-316F6D23-B0B6-4076-B4A8-3F5AE48920D0Q42321286-686A00CE-24E3-4799-A396-96DAD17EAB53Q42926244-D86FE2E8-FE79-4D89-B9B6-F7C1B972B19CQ43519564-190556C7-C273-4576-AB41-B2E5F715260EQ43869407-FD01FFD7-6028-4540-9BEB-074E702F910BQ43878310-9012C6C7-9E4D-4149-9144-0133A972B064Q43889519-E86F37DB-B67E-43B5-911B-628F8E679EBEQ44216598-2616B8F7-E618-4985-9F30-52AFB94E210BQ44355937-514367B7-3BB0-40F7-B62F-5678E6992F04Q45130062-6124194C-726D-4289-870A-A48DB8CD9FE3Q45926800-CE7EB403-BA5D-4DC6-81E4-CF29CD3243B7Q46054107-A180901E-81F3-40C3-9750-05001738D64BQ46256408-C53EA647-9715-4765-92FD-E3DEA4DFEF29Q46952656-737935B2-6B3B-4CFA-B858-E56485E57350Q47276410-4B44EF85-0EDE-4B8A-9914-A84203EB022CQ47301313-576895A5-FE7F-46C9-A8F3-C6DAF416F884Q47365742-44223D55-7E74-4DED-8781-EAF25DC28A96Q47411811-3FFFDF05-98E2-45E1-84A5-C9E6D129727BQ47412476-3E7602EA-62CA-4617-9009-069B0DB8E5CAQ47595204-A7C4655B-0BB4-46E4-B14D-5755C737C152Q47856748-34A96C22-FE03-4A6C-B184-EF917282A5E8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frank Bretz
@ast
Frank Bretz
@en
Frank Bretz
@es
Frank Bretz
@nl
type
label
Frank Bretz
@ast
Frank Bretz
@en
Frank Bretz
@es
Frank Bretz
@nl
prefLabel
Frank Bretz
@ast
Frank Bretz
@en
Frank Bretz
@es
Frank Bretz
@nl
P106
P21
P31
P496
0000-0002-2008-8340